LRIG1 and the liar paradox in prostate cancer: A study of the expression and clinical significance of LRIG1 in prostate cancer

International Journal of Cancer

Volumn 128, Issue 12, 2011, Pages 2843-2852

  Thomasson, Marcus ^a   Wang, Baofeng ^a,f   Hammarsten, Peter ^a   Dahlman, Anna ^b   Persson, Jenny Liao ^c   Josefsson, Andreas ^a   Stattin, Pär ^a   Granfors, Torvald ^d   Egevad, Lars ^e   Henriksson, Roger ^a   Bergh, Anders ^a   Hedman, Håkan ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d CENTRAL HOSPITAL   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

LRIG1; prostate cancer; survival

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; LEUCINE RICH REPEAT AND IMMUNOGLOBULIN LIKE DOMAIN PROTEIN 1; MESSENGER RNA; ONCOPROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TISSUE MICROARRAY;

AGED; AGED, 80 AND OVER; CELL PROLIFERATION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PROSTATECTOMY; PROSTATIC NEOPLASMS; TISSUE ARRAY ANALYSIS;

EID: 79955477797     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25820     Document Type: Article

References (25)

1. The Swedish National Board of Health and Welfare S. Cancer incidence in Sweden In:, Epidemiology Cf, ed., 2006.
2. Parkin DM, Bray F, Ferlay J, Pisani P,. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108. (Pubitemid 40372904)
3. Scher HI, Sawyers CL,. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005; 23: 8253-61. (Pubitemid 46211563)
4. Taplin ME, Balk SP,. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 2004; 91: 483-90.
5. Nilsson J, Vallbo C, Guo D, Golovleva I, Hallberg B, Henriksson R, Hedman H,. Cloning, characterization, and expression of human LIG1. Biochem Biophys Res Commun 2001; 284: 1155-61. (Pubitemid 32917959)
6. Guo D, Holmlund C, Henriksson R, Hedman H,. The LRIG gene family has three vertebrate paralogs widely expressed in human and mouse tissues and a homolog in Ascidiacea. Genomics 2004; 84: 157-65. (Pubitemid 38760139)
7. Gur G, Rubin C, Katz M, Amit I, Citri A, Nilsson J, Amariglio N, Henriksson R, Rechavi G, Hedman H, Wides R, Yarden Y,. LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J 2004; 23: 3270-81. (Pubitemid 39209151)
8. Laederich MB, Funes-Duran M, Yen L, Ingalla E, Wu X, Carraway KL, III, Sweeney C,. The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. J Biol Chem 2004; 279: 47050-6. (Pubitemid 39518360)
9. Shattuck DL, Miller JK, Laederich M, Funes M, Petersen H, Carraway KL, III, Sweeney C,. LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy. Mol Cell Biol 2007; 27: 1934-46.
10. Ledda F, Bieraugel O, Fard SS, Vilar M, Paratcha G,. Lrig1 is an endogenous inhibitor of Ret receptor tyrosine kinase activation, downstream signaling, and biological responses to GDNF. J Neurosci 2008; 28: 39-49.
11. Thomasson M, Hedman H, Guo D, Ljungberg B, Henriksson R,. LRIG1 and epidermal growth factor receptor in renal cell carcinoma: a quantitative RT-PCR and immunohistochemical analysis. Br J Cancer 2003; 89: 1285-9. (Pubitemid 37363418)
12. Miller JK, Shattuck DL, Ingalla EQ, Yen L, Borowsky AD, Young LJ, Cardiff RD, Carraway KL, III, Sweeney C,. Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer. Cancer Res 2008; 68: 8286-94.
13. Hedman H, Nilsson J, Guo D, Henriksson R,. Is LRIG1 a tumour suppressor gene at chromosome 3p14.3? Acta Oncol 2002; 41: 352-4.
14. Tanemura A, Nagasawa T, Inui S, Itami S,. LRIG-1 provides a novel prognostic predictor in squamous cell carcinoma of the skin: immunohistochemical analysis for 38 cases. Dermatol Surg 2005; 31: 423-30. (Pubitemid 40489303)
15. Lindstrom AK, Ekman K, Stendahl U, Tot T, Henriksson R, Hedman H, Hellberg D,. LRIG1 and squamous epithelial uterine cervical cancer: correlation to prognosis, other tumor markers, sex steroid hormones, and smoking. Int J Gynecol Cancer 2008; 18: 312-7. (Pubitemid 351365217)
16. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM,. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004; 6: 1-6. (Pubitemid 38391943)
17. Hedman H, Henriksson R,. LRIG inhibitors of growth factor signalling-double-edged swords in human cancer? Eur J Cancer 2007; 43: 676-82. (Pubitemid 46502902)
18. Egevad L, Granfors T, Karlberg L, Bergh A, Stattin P,. Prognostic value of the Gleason score in prostate cancer. BJU Int 2002; 89: 538-42. (Pubitemid 34948295)
19. Chung SC, Hammarsten P, Josefsson A, Stattin P, Granfors T, Egevad L, Mancini G, Lutz B, Bergh A, Fowler CJ,. A high cannabinoid CB(1) receptor immunoreactivity is associated with disease severity and outcome in prostate cancer. Eur J Cancer 2009; 45: 174-82.
20. Melamed J, Datta MW, Becich MJ, Orenstein JM, Dhir R, Silver S, Fidelia-Lambert M, Kadjacsy-Balla A, Macias V, Patel A, Walden PD, Bosland MC, et al. The cooperative prostate cancer tissue resource: a specimen and data resource for cancer researchers. Clin Cancer Res 2004; 10: 4614-21. (Pubitemid 38955510)
21. Nilsson J, Starefeldt A, Henriksson R, Hedman H,. LRIG1 protein in human cells and tissues. Cell Tissue Res 2003; 312: 65-71. (Pubitemid 36578847)
22. Josefsson A, Wikstrom P, Granfors T, Egevad L, Karlberg L, Stattin P, Bergh A,. Tumor size, vascular density and proliferation as prognostic markers in GS 6 and GS 7 prostate tumors in patients with long follow-up and non-curative treatment. Eur Urol 2005; 48: 577-83. (Pubitemid 41278582)
23. Hammarsten P, Karalija A, Josefsson A, Rudolfsson SH, Wikstrom P, Egevad L, Granfors T, Stattin P, Bergh A,. Low levels of phosphorylated epidermal growth factor receptor in nonmalignant and malignant prostate tissue predict favorable outcome in prostate cancer patients. Clin Cancer Res 2010; 16: 1245-55.
24. Febbo PG, Lowenberg M, Thorner AR, Brown M, Loda M, Golub TR,. Androgen mediated regulation and functional implications of fkbp51 expression in prostate cancer. J Urol 2005; 173: 1772-7. (Pubitemid 40524830)
25. Isalan M, Morrison M,. This title is false. Nature 2009; 458: 969.